MR-146

• MR-146 AAV-NGF is being investigated for the treatment of Stage 2-3 NK^1,2
• Recombinant hNGF is currently the only FDA-approved medication for NK^3,4
• MR-146 is an injectable recombinant hNGF gene designed to be delivered directly to the lacrimal gland via ETF™ Gene Therapy^* using an AAV^1,2
• A preclinical trial observed high levels of hNGF expression in tear film²

The use of MR-146 for Neurotropic Keratopathy is currently being investigated and its safety and efficacy have not been established.

*ETF™ Gene Therapy is an investigational approach to therapy for ocular surface diseases that has not been tested in humans or approved for use in any country.²

AAV, adeno-associated virus; ETF™, Enriched Tear Film; FDA, Food and Drug Administration; hNGF, human nerve growth factor; NK, neurotrophic keratopathy.

1. https://investor.viatris.com/static-files/8ad63891-ba98-4c42-b103-30ba7946e5e4;
2. https://www.ophthalmologytimes.com/view/oyster-point-pharma-unveils-preclinical-study-results-for-enriched-tear-film-gene-therapy-to-target-ocular-surface-diseases;
3. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761094Orig1s000MedR.pdf;
4. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761094s012s013lbl.pdf.